New Delhi: AbbVie Inc on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
Also Read: AbbVie, Teva finalize USD 6.6 billion US opioid settlements
The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion.
AbbVie also expects peak sales of the drugs to exceed $21 billion in 2027. The two drugs are part of the company's long-term growth strategy to offset Humira's loss of exclusivity.
The drug maker has been in contract negotiations with insurers and pharmacy benefit managers for Humira for this year, and said in October that pricing of its rivals would determine the drug's sales this year.
Also Read: Abbvie RINVOQ gets European Commission nod for treatment of Active Non-Radiographic Axial Spondyloarthritis in adults
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!